Enzalutamide treatment slightly, but insignificantly, suppressed tumor PSA expression (p = 0.28), APO treatment significantly suppressed PSA (p = 0.029), and the combination treatment further reduced the PSA levels (p = 0.0053) (Fig. 6i). The gene discussed is KLK3; the disease is neoplasm.